Estrogen receptor-α signaling in post-natal mammary development and breast cancers | SpringerLink
A Selective Ligand for Estrogen Receptor Proteins Discriminates Rapid and Genomic Signaling
Regulation of estrogen receptor signaling in breast carcinogenesis and breast cancer therapy. - Abstract - Europe PMC
Endocrinotherapy resistance of prostate and breast cancer: Importance of the NF‑κB pathway (Review)
The NF-KB pathway and endocrine therapy resistance in breast cancer in: Endocrine-Related Cancer Volume 26 Issue 6 (2019)
The role of estrogen receptor beta in breast cancer | Biomarker Research | Full Text
Fulvestrant-Induced Cell Death and Proteasomal Degradation of Estrogen Receptor α Protein in MCF-7 Cells Require the CSK c-Src Tyrosine Kinase | PLOS ONE
Crossroads of Estrogen Receptor and NF-κB Signaling | Science's STKE
Dual-mechanism estrogen receptor inhibitors | PNAS
Transrepression of estrogen receptor and NFκB. (a) NFκB can inhibit... | Download Scientific Diagram
A Selective Ligand for Estrogen Receptor Proteins Discriminates Rapid and Genomic Signaling.,Cell Chemical Biology - X-MOL
Frontiers | Estrogen Signaling in ERα-Negative Breast Cancer: ERβ and GPER
Estrogen receptor signaling as a target for novel breast cancer therapeutics - ScienceDirect
Cross-talk between nuclear receptors and nuclear factor κB | Oncogene
IJMS | Free Full-Text | Estrogen Receptors-Mediated Apoptosis in Hormone-Dependent Cancers | HTML
Selective Estrogen Receptor Degraders (SERDs): A Promising Strategy for Estrogen Receptor Positive Endocrine-Resistant Breast Cancer | Journal of Medicinal Chemistry
Estrogen receptor functional domains and signal transduction schemes.... | Download Scientific Diagram
EREs).
New insights into acquired endocrine resistance of breast cancer
Impact of Apparent Antagonism of Estrogen Receptor β by Fulvestrant on Anticancer Activity of 2-Methoxyestradiol | Anticancer Research
Estrogen Receptor Pathway | Progestogen Rectieptor Signaling
The NF-KB pathway and endocrine therapy resistance in breast cancer in: Endocrine-Related Cancer Volume 26 Issue 6 (2019)
Distinct mechanisms of resistance to fulvestrant treatment dictate level of ER independence and selective response to CDK inhibitors in metastatic breast cancer | Breast Cancer Research | Full Text
